{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:04:26Z","timestamp":1789473866407,"version":"build-2803163510"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.omtm.2023.08.002","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T01:29:41Z","timestamp":1691544581000},"page":"474-483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Paving the way for future gene therapies: A case study of scientific spillover from delandistrogene moxeparvovec"],"prefix":"10.1016","volume":"30","author":[{"given":"Damon","family":"Asher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa C.","family":"Klimchak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Sedita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Gooch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8966-5177","authenticated-orcid":false,"given":"Louise","family":"Rodino-Klapac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2023.08.002_bib2","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2011-09-382317","article-title":"Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer","volume":"119","author":"Buchlis","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2023.08.002_bib3","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtm.2023.08.002_bib4","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2023.08.002_bib5","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/archdischild-2014-306366","article-title":"Improving recognition of Duchenne muscular dystrophy: a retrospective case note review","volume":"99","author":"van Ruiten","year":"2014","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.omtm.2023.08.002_bib6","first-page":"755","article-title":"Analyzing the concept of spillover effects for expanded inclusion in health economics research","volume":"9","author":"Muir","year":"2020","journal-title":"Methodology"},{"key":"10.1016\/j.omtm.2023.08.002_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jval.2016.12.005","article-title":"Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis","volume":"20","author":"Garrison","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.omtm.2023.08.002_bib8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","article-title":"Defining elements of value in health care-a health economics approach: an ISPOR Special Task Force report [3]","volume":"21","author":"Lakdawalla","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.omtm.2023.08.002_bib9","article-title":"Reimbursement of licensed cell and gene therapies across the major European healthcare markets","volume":"3","author":"J\u00f8rgensen","year":"2015","journal-title":"J.\u00a0Mark. Access Health Policy"},{"key":"10.1016\/j.omtm.2023.08.002_bib10","first-page":"22","article-title":"The three-way pendulum of healthcare innovation","volume":"2","author":"Horgan","year":"2017","journal-title":"Biomed. Hub"},{"key":"10.1016\/j.omtm.2023.08.002_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J.\u00a0Biomed. Sci."},{"key":"10.1016\/j.omtm.2023.08.002_bib13","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2023.08.002_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/COH.0000000000000154","article-title":"History of passive antibody administration for prevention and treatment of infectious diseases","volume":"10","author":"Graham","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.omtm.2023.08.002_bib15","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/19420862.2016.1212149","article-title":"Phage display-derived human antibodies in clinical development and therapy","volume":"8","author":"Frenzel","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.omtm.2023.08.002_bib16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/bioengineering1040188","article-title":"Trends in upstream and downstream process development for antibody manufacturing","volume":"1","author":"Gronemeyer","year":"2014","journal-title":"Bioengineering"},{"key":"10.1016\/j.omtm.2023.08.002_bib17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/d41573-021-00079-7","article-title":"FDA approves 100th monoclonal antibody product","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtm.2023.08.002_bib18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","article-title":"The tangled history of mRNA vaccines","volume":"597","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2023.08.002_bib19","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in\u00a0vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omtm.2023.08.002_bib22","author":"Moderna"},{"key":"10.1016\/j.omtm.2023.08.002_bib23","author":"Pfizer"},{"key":"10.1016\/j.omtm.2023.08.002_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","article-title":"Population frequencies of inherited neuromuscular diseases--a world survey","volume":"1","author":"Emery","year":"1991","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2023.08.002_bib26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2023.08.002_bib28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib29","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.ymthe.2019.07.017","article-title":"AAV-PHP.B administration results in a differential pattern of CNS biodistribution in non-human primates compared with mice","volume":"27","author":"Liguore","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib30","author":"Neurogene"},{"key":"10.1016\/j.omtm.2023.08.002_bib31","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","article-title":"Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR","volume":"26","author":"Cehajic-Kapetanovic","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.08.002_bib33","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ophtha.2015.10.025","article-title":"Gene therapy for Leber hereditary optic neuropathy: initial results","volume":"123","author":"Feuer","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtm.2023.08.002_bib34","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","article-title":"Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial","volume":"374","author":"Maguire","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2023.08.002_bib35","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.08.002_bib36","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2023.08.002_bib37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/14712598.2020.1725469","article-title":"Clinical development on the frontier: gene therapy for duchenne muscular dystrophy","volume":"20","author":"Asher","year":"2020","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib40","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.omtm.2021.02.014","article-title":"Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec","volume":"21","author":"Day","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2023.08.002_bib41","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1208\/s12248-017-0153-x","article-title":"Recommendations for the assessment and management of pre-existing drug-reactive antibodies during biotherapeutic development","volume":"19","author":"Xue","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.omtm.2023.08.002_bib42","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/mt.2013.244","article-title":"Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib43","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy; a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtm.2023.08.002_bib44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/cells11040687","article-title":"Outcome measures in facioscapulohumeral muscular dystrophy clinical trials","volume":"11","author":"Ghasemi","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.omtm.2023.08.002_bib45","article-title":"Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8 years) with Duchenne muscular dystrophy: 1-year interim results from Study SRP-9001-103 (ENDEAVOR)","author":"Zaidman","year":"2021","journal-title":"Ann. Neuro."},{"key":"10.1016\/j.omtm.2023.08.002_bib46","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy","volume":"44","author":"Day","year":"2021","journal-title":"Drug Saf."},{"key":"10.1016\/j.omtm.2023.08.002_bib47","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.omtm.2023.08.002_bib48","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2021","journal-title":"J. Pediatr."},{"key":"10.1016\/j.omtm.2023.08.002_bib49","series-title":"Prescribing Information","author":"Zolgensma","year":"2021"},{"key":"10.1016\/j.omtm.2023.08.002_bib50","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.xphs.2021.03.024","article-title":"Manufacturing challenges and rational formulation development for AAV viral vectors","volume":"110","author":"Srivastava","year":"2021","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.omtm.2023.08.002_bib51","first-page":"1","article-title":"A technology roadmap for today\u2019s gene therapy manufacturing challenges","author":"Carbonell","year":"2019","journal-title":"Cell Gene"},{"key":"10.1016\/j.omtm.2023.08.002_bib52","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1089\/hum.1998.9.16-2353","article-title":"High-titer adeno-associated viral vectors from a Rep\/Cap cell line and hybrid shuttle virus","volume":"9","author":"Gao","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib53","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/sj.gt.3300807","article-title":"Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus","volume":"6","author":"Liu","year":"1999","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib54","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/biot.201400438","article-title":"The baculovirus expression vector system: a commercial manufacturing platform for viral vaccines and gene therapy vectors","volume":"10","author":"Felberbaum","year":"2015","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.omtm.2023.08.002_bib55","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1152\/physrev.00028.2001","article-title":"Function and genetics of dystrophin and dystrophin-related proteins in muscle","volume":"82","author":"Blake","year":"2002","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.omtm.2023.08.002_bib56","series-title":"GeneReviews\u00ae","article-title":"Dystrophinopathies","author":"Darras","year":"2000"},{"key":"10.1016\/j.omtm.2023.08.002_bib57","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/hmg\/11.16.1807","article-title":"Spectrin-like repeats from dystrophin and alpha-actinin-2 are not functionally interchangeable","volume":"11","author":"Harper","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2023.08.002_bib58","doi-asserted-by":"crossref","first-page":"27305","DOI":"10.1074\/jbc.270.45.27305","article-title":"Identification and characterization of the dystrophin anchoring site on beta-dystroglycan","volume":"270","author":"Jung","year":"1995","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2023.08.002_bib59","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1016\/S0021-9258(19)39599-7","article-title":"Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility","volume":"265","author":"Koenig","year":"1990","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2023.08.002_bib60","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bbapap.2007.12.014","article-title":"Sub-domains of the dystrophin rod domain display contrasting lipid-binding and stability properties","volume":"1784","author":"Legardinier","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtm.2023.08.002_bib61","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1093\/hmg\/ddy113","article-title":"Variable rescue of microtubule and physiological phenotypes in mdx muscle expressing different miniaturized dystrophins","volume":"27","author":"Nelson","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2023.08.002_bib62","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0969-2126(00)00132-5","article-title":"The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy","volume":"8","author":"Norwood","year":"2000","journal-title":"Structure"},{"key":"10.1016\/j.omtm.2023.08.002_bib63","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0014-5793(92)81265-N","article-title":"Glycoprotein-binding site of dystrophin is confined to the cysteine-rich domain and the first half of the carboxy-terminal domain","volume":"308","author":"Suzuki","year":"1992","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omtm.2023.08.002_bib64","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1093\/hmg\/ddw210","article-title":"Dystrophin contains multiple independent membrane-binding domains","volume":"25","author":"Zhao","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2023.08.002_bib65","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2023.08.002_bib66","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/hmg\/4.8.1245","article-title":"Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy","volume":"4","author":"Wells","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2023.08.002_bib67","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/mt.2016.5","article-title":"Current progress in therapeutic gene editing for monogenic diseases","volume":"24","author":"Prakash","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/hgtb.2015.140","article-title":"Expressing transgenes that exceed the packaging capacity of adeno-associated virus capsids","volume":"27","author":"Chamberlain","year":"2016","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.omtm.2023.08.002_bib69","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hep.30535","article-title":"Liver expression of a miniATP7B gene results in long-term restoration of copper homeostasis in a Wilson disease model in mice","volume":"70","author":"Murillo","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.omtm.2023.08.002_bib70","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ymthe.2017.12.019","article-title":"Rescue of GSDiii phenotype with gene transfer requires liver- and muscle-targeted GDE expression","volume":"26","author":"Vidal","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib71","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1089\/hum.2017.049","article-title":"Gene therapy using a minicep290 fragment delays photoreceptor degeneration in a mouse model of Leber congenital amaurosis","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib72","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-0729","article-title":"Gene therapy for spinal muscular atrophy: safety and early outcomes","volume":"146","author":"Waldrop","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.omtm.2023.08.002_bib73","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/08830738211047019","article-title":"Health profile of preterm males with Duchenne muscular dystrophy","volume":"36","author":"Soim","year":"2021","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.omtm.2023.08.002_bib75","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/sj.mt.6300027","article-title":"Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle","volume":"15","author":"Salva","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib77","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1089\/hum.2019.199","article-title":"Preclinical systemic delivery of adeno-associated \u03b1-sarcoglycan gene transfer for limb-girdle muscular dystrophy","volume":"32","author":"Griffin","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib78","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ymthe.2017.02.013","article-title":"Systemic AAV-mediated beta-sarcoglycan delivery targeting cardiac and skeletal muscle ameliorates histological and functional deficits in LGMD2E mice","volume":"25","author":"Pozsgai","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib79","article-title":"Systemic AAV9.BVES delivery ameliorates muscular dystrophy in a mouse model of LGMDR25","author":"Li","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib80","first-page":"e28","article-title":"Empower multiplex cell and tissue-specific CRISPR-mediated gene manipulation with self-cleaving ribozymes and tRNA","volume":"45","author":"Xu","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2023.08.002_bib81","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/mt.2015.192","article-title":"CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice","volume":"24","author":"Xu","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib82","first-page":"4","article-title":"A collaborative analysis by clinical trial sponsors and academic experts of anti-transgene SAEs in studies of gene therapy for DMD","volume":"30","author":"Bonnemann","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib84","author":"O'Shea"},{"key":"10.1016\/j.omtm.2023.08.002_bib85","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2023.08.002_bib86","author":"Harris"},{"key":"10.1016\/j.omtm.2023.08.002_bib87","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-associated defective virus particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"key":"10.1016\/j.omtm.2023.08.002_bib88","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.175.4025.949","article-title":"Gene therapy for human genetic disease?","volume":"175","author":"Friedmann","year":"1972","journal-title":"Science"},{"key":"10.1016\/j.omtm.2023.08.002_bib89","first-page":"2072","article-title":"A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase","volume":"4","author":"Tratschin","year":"1984","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omtm.2023.08.002_bib90","doi-asserted-by":"crossref","first-page":"6466","DOI":"10.1073\/pnas.81.20.6466","article-title":"Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells","volume":"81","author":"Hermonat","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2023.08.002_bib91","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/hum.1991.2.3-251","article-title":"Draft of FDA's Points to Consider in human somatic cell therapy and gene therapy","volume":"2","year":"1991","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib92","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nm0397-306","article-title":"Recombinant adeno-associated virus for muscle directed gene therapy","volume":"3","author":"Fisher","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.08.002_bib93","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/hum.1996.7.9-1145","article-title":"A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease","volume":"7","author":"Flotte","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib94","unstructured":"Duchenne, G.B.A. (1861). 2 Edition. In: De l'electrisation localisee et de son application a la pathologie et a la therapeutique, 2, (Paris), pp. 353-356."},{"key":"10.1016\/j.omtm.2023.08.002_bib95","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1073\/pnas.81.4.1189","article-title":"X chromosome-linked muscular dystrophy (mdx) in the mouse","volume":"81","author":"Bulfield","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2023.08.002_bib96","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/323646a0","article-title":"Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene","volume":"323","author":"Monaco","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2023.08.002_bib97","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2023.08.002_bib98","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2023.08.002_bib99","first-page":"3148","article-title":"[Introduction of rod-deleted dystrophin cDNA, delta DysM3, into mdx skeletal muscle using adenovirus vector]","volume":"55","author":"Yuasa","year":"1997","journal-title":"Nihon Rinsho."},{"key":"10.1016\/j.omtm.2023.08.002_bib100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1479-5876-5-45","article-title":"A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy","volume":"5","author":"Rodino-Klapac","year":"2007","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.omtm.2023.08.002_bib101","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/mt.2015.9","article-title":"Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA Mice","volume":"23","author":"Duncan","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib102","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1089\/hum.2019.255","article-title":"Dose-escalation study of systemically delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx mouse model of Duchenne muscular dystrophy","volume":"32","author":"Potter","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.08.002_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1167762","article-title":"Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy","volume":"11","author":"Mendell","year":"2023","journal-title":"Front. Cell Dev. Biol."}],"container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905012300116X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905012300116X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T01:38:02Z","timestamp":1714786682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S232905012300116X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":92,"alternative-id":["S232905012300116X"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2023.08.002","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paving the way for future gene therapies: A case study of scientific spillover from delandistrogene moxeparvovec","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2023.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}]}}